RNA viruses are the agents of numerous widespread and often severe diseases. Their unique RNA-dependent RNA polymerase (RDRP) is essential for replication and, thus, constitutes a valid target for the development of selective chemotherapeutic agents. In this regard, we have investigated sugar-modified ribonucleoside analogues as potential inhibitors of the RDRP. Title compounds retain 'natural' pyrimidine bases, but possess a β β-methyl substituent at the 2′-position of the D-or L-ribose moiety. Evaluation against a broad range of RNA viruses, either single-stranded positive (ssRNA + ), single-stranded negative (ssRNA -) or double-stranded (dsRNA), revealed potent activities for D-2′-C-methyl-cytidine and -uridine against ssRNA + , and dsRNA viruses. None of the L-enantiomers were active. Moreover, the 5′-triphosphates of the active D-enantiomers were found to inhibit the bovine virus diarrhoea virus polymerase. Thus, the 2′-methyl branching of natural pyrimidine ribonucleosides transforms physiological molecules into potent, broad-spectrum antiviral agents that merit further development.
Introduction
RNA viruses are major human pathogens causing millions of deaths annually. We can cite dengue fever virus (50 million cases annually; World Health Organization, 2002), hepatitis C virus (HCV; >170 million infections worldwide; World Health Organization, 2000), enteroviruses (80% of meningitis cases are viral; Van Vliet et al., 1998) , influenza viruses (>100 million cases annually; World Health Organization, 2003) , measles viruses (>20 million cases annually and 39 people die every hour; World Health Organization, 2007) and gastroenteritis viruses (>1 million deaths annually; Parashar et al. 2003) as major human pathogens. Moreover, we are now experiencing the negative impact of emerging RNA viruses as evidenced by the enormous economic cost of the recent severe acute respiratory syndrome (SARS) outbreak and the threat of the potential use of RNA viruses as bioterrorism weapons.
Currently, more than 350 species of RNA viruses have been described, and, according to genome structure and expression modalities, they can be classified as singlestranded positive RNA (ssRNA + ), single-stranded negative RNA (ssRNA -), and double-stranded RNA (dsRNA) viruses. Besides the Retroviridae, and its representative member HIV, notable examples of severehuman-disease-causing ssRNA + virus families are Flaviviridae, Picornaviridae and Coronaviridae. Human pathogen ssRNAviruses include Paramyxoviridae (of which the pneumovirus respiratory syncytial virus [RSV] still requires antiviral approaches to treat its infection) and Rhabdoviridae (such as rabies virus and vesicular stomatitis virus [VSV] ), which with Filoviridae (such as Ebola virus; Driscoll, 2002) are among the most deadly viruses to infect humans (De Clercq, 2004) . Finally, Reoviridae, such as reoviruses and rotaviruses, are dsRNA viruses associated with worldwide epidemics of viral gastrointestinal infections (De Clercq, 2004) .
Although efficacious drugs have been developed to treat infections caused by DNA viruses and to control those from retroviruses, no specific antiviral drugs are available for the prevention or the treatment of infections caused by the majority of RNA viruses. Perhaps the only exception is represented by the HCV, the agent of the currently most common blood-borne infection. Indeed, the prevalence of HCV infection is now thought to be approximately fivefold greater than HIV infection . The current therapy for chronic hepatitis C Hugle & Cerny 2003; Walker et al., 2003; McHutchison et al., 2006) consists of pegylated interferonα together with the nucleoside analogue ribavirin. However, both interferon and ribavirin are poorly tolerated and have limited efficacy, with no more than a 30% response rate among patients infected with the most prevalent HCV genotype (1b; Walker & Hong, 2002) . Therefore, there is an urgent need for more efficient and better tolerated anti-HCV agents, as well as for specific and selective treatments against a higher number of RNA virus infections.
The success of antiviral therapies based on chemotherapeutic agents targeting viral polymerases prompted us to consider the RNA-dependent RNA polymerase (RDRP) as a target. The examples of herpes virus DNA polymerases and of HIV and hepatitis B virus (HBV) reverse transcriptases demonstrate the clinical use of nucleoside inhibitors, which function, after metabolization to their triphosphorylated derivatives, as competitors of the natural nucleotide substrates. In the case of RDRP enzymes, the natural substrates are the triphosphorylated derivatives of ribonucleosides and it appeared to us that an investigation of sugar-modified ribonucleoside analogues as inhibitors of RNA virus replication would be worthwhile.
As part of an ongoing effort to develop new chemotherapeutic agents against RNA viruses, principally against Flaviviridae, our group was first to identify and report a series of branched-sugar ribonucleosides that could act as potential chemotherapeutic agents (Sommadossi & La Colla 2001a; Sommadossi & La Colla 2001b) . Here we report a detailed study dealing with a potent class of 2′-Cmethylribonucleosides in the pyrimidine series, bearing a β-methyl substituent at the 2′-position of the sugar moiety, although the aglycone was kept natural. Syntheses of the 2′-C-methyl branched ribonucleosides derived from the three naturally occurring pyrimidine bases are described, as well as their evaluation in cell-based assays employing viruses representative of the ssRNA + , ssRNA -, and dsRNA classes. Encouraged by results obtained with other L-nucleoside analogues in HIV and HBV chemotherapies (Mathé C & Gosselin G, 2006) , we also decided to include in the present study the preparation and antiviral evaluation of the corresponding hitherto unknown L-enantiomers. Bis(S-acyl-2-thioethyl) (SATE) phosphotriester derivatives of the 2′-methyl branched D-and L-ribonucleosides were also synthesized. These compounds were designed as nucleotidic (Krise & Stella 1996; Schultz 2003; Cahard et al., 2004; Drontle & Wagner 2004; Meier et al., 2004; Peyrottes et al., 2004) , that is, the ionizable phosphate groups have been neutralized via chemical derivatization of the phosphorus-coupled oxygens to form neutral esters. Such prodrugs are thus able to diffuse across the plasma membrane or other biological barriers, and to regenerate the monophosphate derivative after hydrolysis of the masking groups. Moreover, corresponding triphosphate derivatives were prepared and assayed against bovine virus diarrhoea virus (BVDV) polymerase, in order to assess an RNA-polymerase-inhibition-based mode of action. Finally, some compounds were chosen for further studies to determine cellular metabolism, physicochemical properties and rat toxicities, in order to permit the selection of a potential candidate suitable for clinical development.
Materials and methods

Chemistry
Experimental description is reported in the supplemental information to this manuscript (see additional file online).
Virology
Compounds. Compounds were dissolved in DMSO at 100 mM and then diluted in culture medium.
Cells. Cell lines were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). The absence of mycoplasma contamination was checked periodically by the Hoechst staining method. Cell lines supporting the multiplication of RNA viruses were as follows: Madin-Darby bovine kidney (MDBK; Madin & Darby Jr, 1958) , baby hamster kidney (BHK-21), monkey kidney (Vero 76) and human lung squamous carcinoma (SK-MES-1) cells.
Cytotoxicity assays
For cytotoxicity tests, which were run in parallel with antiviral assays, MDBK, BHK, Vero 76 and SK-MES-1 cells were seeded in 96-well plates (BD Falcon, BD Biosciences, San Jose, CA, USA) at an initial density of 6×10 5 , 1×10 6 , 5×10 5 and 6×10 5 cells/ml, respectively, in growth medium, with or without serial dilutions of test compounds. Cell viability was determined after 48-96 h at 37˚C in a humidified CO 2 (5%) atmosphere by the 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method (Pauwels et al., 1998) . The cell number of Vero 76 and SK-MES-1 monolayers was determined by staining with the methylene blue dye.
For cytotoxicity evaluations, exponentially growing cells derived from human haematological tumours (CD4 + human T-cells containing an integrated human Tlymphotropic virus genome -5]) were also seeded at 1×10 5 cells/ml in 96-well plates in cell-type-specific media supplemented with 10% FCS and antibiotics as described above. Cell cultures were then incubated at 37˚C in a humidified 5% CO 2 atmosphere in the absence or presence of serial dilutions of test compounds. Cell viability was determined after 96 h at 37˚C by the MTT method (Pauwels et al., 1998) .
Antiviral assay
HIV-1 assay. Activity of compounds against HIV was measured by the inhibition of virus-induced cytopathogenicity in MT-4 cells acutely infected with HIV at multiplicity of infection (m.o.i.) of 0.01. Briefly, 50 μl of RPMI containing 1×10 4 MT-4 cells was added to each well of flat-bottom microtitre trays containing 50 μl of RPMI with or without serial dilutions of test compounds. Then, 20 μl of an HIV-1 suspension containing 100 50% cell culture infective doses were added. After a 4-day incubation, cell viability was determined by the MTT method (Pauwels et al., 1998) .
YFV-, DENV-2-, WNV-, Reo-1 and BVDV-preinfected cell assays. Activity of compounds against yellow fever virus (YFV, 17D vaccine strain), dengue virus type 2 (DENV-2, clinical isolate), West Nile virus (WNV, clinical isolate) and reovirus type 1 (Reo-1) was measured by the inhibition of virus-induced cytopathogenicity in acutely infected BHK-21 cells. Activities against BVDV in infected MDBK cells and against RSV (A-2 strain) in infected Vero 76 cells were also based on inhibition of virus-induced cytopathogenicity.
BHK, MDBK and Vero 76 cells were seeded in 96-well plates at a density of 5×10 4 and 3×10 4 and 2.5×10 4 cells/well, respectively, and were allowed to form confluent monolayers by incubating overnight in growth medium at 37˚C in a humidified CO 2 (5%) atmosphere. Cell monolayers were then infected with 50 μl of a proper virus dilution (in serum-free medium) to give an m.o.i of 0.01 (0.1 in the case of RSV). After 1 h, 50 μl of modified Eagle's medium (MEM) Earle's medium (Dulbecco's MEM [DMEM] for Vero/RSV) supplemented with inactivated FCS (1% final concentration) with or without serial dilutions of test compounds was added. After a 3-day incubation (5 days for Vero/RSV) at 37˚C, cell viability was determined by the MTT method. In the case of Vero/RSV, cell viability was determined with crystal violet staining of the monolayer (see below), followed by optical density determination of the dye recovered from the monolayer, which was solubilized with a solution containing 1% sarkosyl and HEPES 10%, by spectrophotometer at 570 nm.
BVDV-pretreated cell protection assay. MDBK cells were maintained in DMEM supplemented with 8% heat inactivated horse serum (HS), 2 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin and 25 mM HEPES. They were grown at 37˚C in a humidified 5% CO 2 atmosphere. Cytopathic BVDV strain NADL was obtained from ATCC.
MDBK cells were plated onto Primaria 96-well plates (BD Biosciences) at 4×10 3 cells/well 24 h before use. Then 100 μl of test compound dilution was added to cells, followed by 100 μl of virus inoculum. The m.o.i (0.04) was selected to destroy 85-95% of the cell monolayer after 3 days. Each drug dilution was tested four times on both infected and uninfected cells. After 3 days, cells were fixed with 3.7% formaldehyde and then stained with 1% crystal violet. After rinsing and resuspension in 50% ethanol, the optical density of the wells was read at 560 nm in a microplate reader (Fusion, Perkin Elmer Life and Analytical Sciences, Inc, Waltham, MA, USA). The EC 50 value was defined as the concentration of compound that protected 50% of cells from virally induced cytopathic effect.
CVB-2, Polio-1, WNV, HCoV, and VSV assays. Activity of compounds against Coxsackie virus, B-2 strain (CVB-2); poliovirus type-1 (Polio-1), Sabin strain; human corona virus (HCoV), strain 229E; and vesicular stomatitis virus (VSV) was determined by plaque reduction assays in Vero 76 cell monolayers. Vero 76 cells (SK-MES-1 for HCoV) were seeded in 24-well plates at a density of 2.5x10 5 cells/well and were allowed to form confluent monolayers by incubating overnight in growth medium at 37˚C in a humidified CO 2 (5%) atmosphere. Then, monolayers were infected with 250 μl of proper virus dilutions to give 50-100 plaque-forming units/well. Following the removal of unadsorbed virus, 500 μl of DMEM (MEM Earle's for HCoV) supplemented with 1% inactivated FCS and 0.75% methyl cellulose with or without serial dilutions of test compounds were added. Cultures were incubated at 37˚C for 2 (Sb-1 and VSV), 3 (CVB-2) or 4 (HCoV) days, fixed with phosphate-buffered saline (PBS) containing 50% ethanol and 0.8% crystal violet, washed and air-dried. Plaques were then counted. EC 50 was calculated by linear regression technique.
HCV replicon assays. Huh-7 cells containing HCV Con1 subgenomic replicon (GS4.1 cells), kindly provided by C Seeger (Fox Chase University, Philadelphia, PA, USA), were grown in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 110 mg/l sodium pyruvate, 0.1 mM nonessential amino acids, 100 U/ml penicillin-streptomycin and 0.5 mg/ml G418 (Invitrogen Corp, Carlsbad, CA, USA). For dose-response testing, the cells were seeded in 96-well plates at 7.5×10 3 cells/well in a volume of 50 μl and incubated at 37˚C/5% CO 2 . Three hours after plating, 50 μl of 10 twofold serial dilutions of compounds (highest concentration, 75 μM) were added and cell cultures were incubated at 37˚C/5% CO 2 in the presence of 0.5% DMSO. Alternatively, compounds were tested at a single concentration of 15 μM. In all cases, Huh-7 cells lacking the HCV replicon served as a negative control. The cells were incubated in the presence of compounds for 72 h after which they were monitored for expression of the NS4A protein by ELISA. For this, the plates were then fixed for 1 min with 1:1 acetone-methanol, washed twice with PBS containing 0.1% Tween 20, blocked for 1 h at room temperature with TNE buffer containing 10% FBS and then incubated for 2 h at 37˚C with the anti-NS4A mouse monoclonal antibody A-236 (ViroGen, Watertown, MA, USA) diluted in the same buffer. After washing three times with PBS containing 0.1% Tween 20, the cells were incubated for 1 h at 37˚C with anti-mouse immunoglobulin G-peroxidase conjugate in TNE buffer with 10% FBS. After washing as described above, the reaction was developed with O-phenylenediamine (Zymed, San Francisco, CA, USA). The reaction was stopped after 30 min with 2 N H 2 SO 4 and the absorbance was read at 492 nm using Sunrise Tecan (Durham, NC, USA) spectrophotometer. EC 50 values were determined from the % inhibition versus concentration data using a sigmoidal non-linear regression analysis based on four parameters with Tecan Magellan software. When screening at a single concentration, the results were expressed as % inhibition at 15 μM. For cytotoxicity evaluation, GS4.1 cells were treated with compounds as described above and cellular viability was monitored using the Cell Titer 96 AQ ueous One Solution Cell Proliferation Assay (Promega Corp, Madison, WI, USA). CC 50 values were determined from the % cytotoxicity versus concentration data with Tecan Magellan software as described above.
BVDV NS5B polymerase assay RDRP assay was performed using a RNA template (-21; Kim et al., 2000) chemically synthesized by Dharmacon (Boulder, CO, USA) and recombinant purified BVDV NS5B provided by C Kao (Texas A&M University, College Station, TX, USA). Standard reaction mixtures consisted of 5 pmol of the (-21) template and 100 ng of BVDV NS5B in the reaction buffer containing 20 mM sodium glutamate pH 8.2, 12 mM DTT, 4 mM MgCl 2 , 1 mM MnCl 2 , 0.5 % (v/v) Triton X-100, 20 U Superase-in (Ambion), 500 μM GTP and 200 μM ATP, UTP or CTP. In compounds 28-30 and 32, correspondent [α 32 P]-NTP (800 Ci/mmol) was added to the final concentration of 250 nM. Compounds were added to a final concentration of 0.4-100 μM. The reaction mixtures were incubated for 60 min at 25˚C. Reactions were transferred onto DE-81 filter paper, washed four times with 2× standard saline citrate solution and once with ethanol, dried and exposed to PhosphoImager screen. Incorporated radioactivity was visualized and quantitated with a PhosphoImager (Molecular Dynamics, Sunnyvale, CA, USA). IC 50 values were determined from plots of compound concentration versus % inhibition of polymerase activity using XLfit software (IDBS, Inc, Burlington, MA, USA).
Chemical Stability
The chemical hydrolysis rates of 4 and 5 were determined in KCl-HCl buffer 0.135 M solution (pH=1.2; 37˚C) and Milli-Q water (pH=6.3; 37˚C).
Test compounds in 10 -4 M solutions were incubated at 37˚C in proper medium. Aliquot samples were collected at different intervals of time and analysed by HPLC on a Waters Associates (Milford, MA, USA) unit (multisolvent delivery system, 717 autosampler injector, 996 photodiode array detector and a Millenium data workstation) using a reverse-phase analytical column (Nova-Pak: Silica 60 Å 4μm, C18, 150 [3.9 mm]). Elution was effected using a linear gradient of 0-25% acetonitrile in 20 mM triethylammonium acetate buffer (pH 7) programmed over a 30-min period with a flow rate of 1 ml/min.
Intracellular metabolism studies
Two cell lines, HepG2 and MDBK, were used to evaluate the intracellular metabolism of [ 3 H]-4 (3.0 Ci/mmol, 99.1% pure; Moravek Biochemicals, Brea, CA, USA) and [ 3 H]-5 (23.9 Ci/mmol, 99.9% pure; Moravek Biochemicals). HepG2 is a human hepatoma cell line and MDBK is a bovine kidney cell line; whereas both are used in the BVDV model. HepG2 cells were cultured in MEM supplemented with non-essential amino acids, 1% L-glutamine, 1% sodium pyruvate, 10% heat-inactivated FBS and 1% penicillin-streptomycin. MDBK cells were cultured in DMEM supplemented with 25 mM HEPES buffer, 1% L-glutamine, 1% sodium pyruvate, 8% heat-inactivated HS and 1% penicillin-streptomycin. Confluent monolayers of either HepG2 or MDBK cells were dispersed using trypsin-EDTA, rinsed and reseeded at 1.5×10 6 cells/well for HepG2 or 8×10 5 cells/well for MDBK. In both cases, cells were 80% confluent at the time of drug addition. The cell monolayers were exposed to 10 μM [ 3 H]-drug (500-1,000 dpm/pmol) for selected times after which the cells were rinsed with cold PBS, collected from the plates and extracted with 70% methanol. The extracts were centrifuged, dried and analysed by HPLC. In addition to the analysis of intracellular samples, aliquots of the exposure medium (both prior to and after exposure to cells) were taken and stored at -20˚C for HPLC analysis without further processing.
Hepatocytes, liver S9 fraction, and liver cytosol assays
The ability of test compounds to function as substrate for relevant metabolic enzymes was examined using human hepatocytes and liver subcellular fractions obtained from BD Gentest (Woburn, MA, USA). Tritiated 5 (23.9 Ci/mmol, 99.9% pure, Moravek Biochemicals) or 4 (3.0 Ci/mmol, 99.1% pure, Moravek Biochemicals) were incubated for 24 h at 10 μM [ 3 H]-drug (500-1,000 dpm/pmol) with hepatocytes in culture, or 1 h at 50-100 μM with 1 mg/ml liver S9 or liver cytosol. Prior to HPLC analysis, samples were quenched with twice the volume of cold 50-50 v/v methanol-acetonitrile, centrifuged, dried and resuspended in HPLC water.
Samples were analysed by ion-pair reverse-phase using an Agilent model 1100 instrument with automatic injection and a diode-array spectrophotometer detector. The mobile phase consisted of buffer A (25 mM potassium phosphate, 5 mM tetrabutyl ammonium phosphate, pH 7.0 and 0.5% methanol) and buffer B (methanol). A multistage linear gradient from 2% to 35% buffer B was run from 0 to 60 min. Radioactivity was analysed by online detection using a 500TR radiomatic detector. Quantitation of each analyte was based on peak areas (radioactivity) from radiochromatograms. When possible, radiolabel peaks were identified by coelution with authentic standards. Further identification was done through digestion of cell extracts with 1-5 units of alkaline phosphatase for 60 min at 37˚C.
Toxicology experiments
Toxicity studies with 5 were conducted in Crl:CD (SD) IGS BR rats and performed by Charles River Laboratories (Worcester, MA, USA). Briefly, the potential acute toxicity of 5 was evaluated in one group of four female rats administered with the test compound in an escalating fashion with single doses of 20 mg/kg (day 1) and 50 mg/kg (day 4) and ending with six consecutive daily doses of 100 mg/kg (day 7-12). In all studies, the test compound was dosed by oral gavage at a volume of 10 mg/kg using 0.5% carboxymethylcellulose as the dosing vehicle. Food and water were provided ad libitum. Toxicity was assessed by clinical observations and body weight measurements.
Results
Chemistry
The 2′-C-methylribonucleosides 3-5 derived from the three naturally occurring pyrimidine bases were synthesized using the strategy reported by Harry-O'kuru et al. (Wolfe & Harry-O'kuru 1995; Harry-O'kuru et al., 1997a; Harry-O'kuru et al., 1997b) , which allows the use of a common peracylated 2′-C-methylribofuranose (1) which can be condensed with the appropriate heterocyclic base (Figure 1 ). This precursor sugar is easily accessible from commercially available material, and 2′-C-methyl-uridine (4) was prepared as described in the literature (Harry-O'kuru et al., 1997b; Tang et al., 1999) , introducing only a slight modification that permitted easy isolation. For practical considerations, we prepared the cytosine derivative (5) converting the uracil nucleoside ( Figure 1 ) via the transient generation of the 4-nitrophenoxy-derivative (Legorburu et al., 1999) . Substitution with aqueous ammonia afforded the desired 2′-C-methyl-cytidine (5) as a crystalline solid with a 73% yield after chromatographic purification. Thymidine derivative 3 (Wolf et al., 1992) was only cited in the previous communication from Harry-O'kuru's group (Harry-O'kuru et al., 1997a) ; no experimental or characterization data were reported. We performed the glycosylation of 1 with thymine under Vorbrüggen-type persilylation conditions , which quantitatively yielded the benzoyl derivative 2a. Deprotection led to 2′-C-methyl-thymidine (3) in 93% after silica gel chromatography.
The strategy chosen for the preparation of the hitherto unknown L-nucleoside derivatives parallels the one mentioned above for the D series and makes use of the key 2′-C-methyl branched perbenzoylated sugar 10 (Figure 2) , the L-enantiomer of 1. In this case, the corresponding precursor 8 (Du et al., 1999) was not as readily available and needed to be synthesized. Starting from L-ribose, compound 6 was obtained following the three-step sequence developed for the corresponding D-enantiomer (Recondo & Rinderknet 1959) , and isolated as its β-anomer by crystallization from ethanol with a 39% overall yield. Hydrogen bromide treatment of 6 followed by water addition led to the bicyclic derivative 7. Compound 7 then rearranged into the desired carbohydrate 8 and into compound 9, which was recycled into the starting sugar 6 by acetylation under acidic conditions. The two rearranged products were easily separated by crystallization of 8 from ethanol, whereas 9 was recovered in the filtrate. L-ribofuranose derivative 8 was converted into 10 through the procedure described for the D series (Harry-O'kuru et al., 1997b) , involving Dess-Martin oxidation of the 2-hydroxyl function and addition of an organotitanium reagent on the resulting 2-keto-ribofuranose. The stereoselectivity for the introduction of the methyl group on the β-face of the sugar was favoured by the steric hindrance of the α-face by the benzoyl groups in the 1 and 3 positions. Perbenzoylation of the different compounds generated during this step (Harry-O'kuru et al., 1997b) afforded the common key synthon 10 in a 51% overall yield from 8, after purification by chromatography on silica gel. Condensation of 10 with the appropriate nucleobase, following procedures similar to those used in the D series, afforded the corresponding protected L-nucleosides 11a-b (Figure 2) . The free L-nucleosides 12 and 13 bearing the thymine and uracil bases, respectively, were finally obtained by simple ammonolysis, whereas the cytosine analogue 14 was synthesized by conversion of the uracil derivative 13 ( Figure 2 ).
Preparation of monophosphate prodrugs derived from 2′-C-methyl branched uridine and cytidine, compounds 19 and 20 (Figure 3 ) in the D series and 25 and 26 (Figure 4 ) for the L series required protection for the secondary and tertiary hydroxyls of the corresponding starting free nucleosides. Condensation of the isopropylidene-protected derivatives with bis(S-pivaloyl-2-thioethyl) N,Ndiisopropylphosphoramidite (Lefebvre et al., 1995) , followed by in situ oxidation led respectively to 17 and 18 (or 23 and 24 in the case of the L derivatives). Acidic treatment afforded the desired bis(tBuSATE)phosphotriesters 19, 20, 25 and 26.
For the synthesis of the triphosphate derivatives of the three nucleosides in the D series (compounds 3-5), we selected the phosphorus oxychloride method (Ludwig 1981; Fischer et al., 1993; Burgess & Cook 2000) for its selectivity, permitting the use of unprotected nucleosides. Triphosphate derivatives 28-30 ( Figure 5 ) of 2′-C-methylthymidine, -uridine and -cytidine, respectively, were thus obtained with yields in the range of 20-30% after purification. Interestingly, the synthesis and purification methods applied, consisting in a sequence of Sephadex chromatography and semi-preparative HPLC, gave access to quantities enabling full characterization, and conversion to easily handled powder-form sodium salts. A similar procedure was used for the preparation of the triphosphorylated L-uridine derivative 32 ( Figure 5 ).
Broad antiviral and toxicity evaluations in cell culture experiments
Title compounds were evaluated in cell-based assays against viruses representative of three genera of the Flaviviridae, that is, Pestivirus (BVDV; Table 4 ), and finally against a virus representative of dsRNA families, that is, Reoviridae (Reo-1; Table 2 ).
For BVDV (Table 1) , we have reported two sets of results obtained from two different test systems using different virus strains, protocols and read-outs. The two systems showed broadly similar results for the activity of individual compounds, and for the potency order within a series of compounds.
Unlike the thymidine derivative (3), the cytosine D-nucleoside (5) was shown to be active against the ssRNA + pestiviruses, flaviviruses, enteroviruses, and coronaviruses, but not against HIV-1 (Tables 1, 2 & 4) . The 2′-C-methyluridine (4) showed appreciable activity against BVDV (Table 1) , but was only marginally active against flaviviruses (Table 2) and enteroviruses (Table 4 ). On the other hand, cytidine derivative 5 was four to eightfold more potent than its uridine counterpart 4 against CVB-2, Polio-1 (Table 4) , Reo-1 (Table 2) and BVDV (Table 1) ; against BVDV, 5 exhibited activities in the low micromolar range without any toxicity for the host's cell lines ≤100 μM (Table 1) .
2′-C-Methyl-cytidine (5) also showed some activity against the dsRNA reovirus (Reo-1, Table 2 ). None of the D-nucleosides exhibited any inhibition against the ssRNArepresentatives belonging to the paramyxoviruses and rhabdoviruses (Table 4) .
Concerning the toxicity evaluation of the title compounds for the cell lines sustaining viral replication (Tables 1, 2 & 4), cytotoxicity assays in MDBK, BHK, Vero and SK-MES-1 cells were run in parallel with antiviral assays in confluent monolayers. However, the cytotoxicity studies for MT-4 cells (Table 1) , as well as for the human cell lines derived from haematopoietic and solid tumours, and also for 'normal' foreskin and lung fibroblasts (Table 5) , were run in exponentially growing cultures. D-nucleosides 3 and 4 did not show any cytotoxicity in the tested cell lines and the cytidine derivative 5 was only moderately toxic for MT-4, CCRF-CEM, WIL-2NS, CCRF-SB and HepG2 cells.
Regarding the antiviral evaluation of the 2′-C-methyl branched L-ribonucleosides 12-14 (Tables 1, 2 & 4), neither activity against the different classes of RNA viruses nor toxicity towards the cell hosts was found (Tables 1, 2, 4 & 5) . To verify if the lack of activity for 12-14 might be attributed to a problem of intracellular phosphorylation, we synthesized and evaluated the nucleotidic prodrugs 25 and 26, which were derived from compounds 13 and 14 respectively, as representative examples of the L-series.
Unfortunately, compounds 25 and 26 showed no antiviral activity against all the tested RNA viruses (Tables 1, 2, & 4), just as their parent derivatives 13 and 14. As a control, we decided to investigate the same kind of modification on the D-2′-C-methylribonucleosides 4 and 5. Unlike its L-counterpart 25, the uracil phosphotriester derivative 19 resulted in significantly (5-20-fold) more potency than its parent compound 4 against both ssRNA + and dsRNA viruses (Tables 1, 2 & 4). A similar increase in potency was observed for the cytosine phosphotriester derivative 20, except against BVDV (Table 1 ) and the enteroviruses (Table 4) , for which the same potency as 5 was maintained. It should, however, be noted that the prodrugs also led to a greater cytotoxicity (Tables 1, 2, 4 &  5) , which could be related to an increased intracellular accumulation of one of the phosphorylated derivatives. As shown in Table 5 , 20 was the sole compound that was systematically cytotoxic (CC 50 range 8-31 μM) for all the exponentially growing cells. Interestingly, L phosphotriester derivatives 25 and 26 were devoid of any cytotoxicity effects (Tables 1, 2 , 4 & 5) . In the absence of a robust infectious HCV replication assay, the title compounds were evaluated in a HCV Con1 subgenomic replicon assay that allows HCV RNA replica-tion in the human hepatoma cells (Huh-7). As seen for BVDV, only the 2′-C-methyl-uridine (4) and the cytidine derivative (5) showed appreciable activity against HCV (Table 3 ). In this case, however, the 2′-C-methyl-cytidine (5) was 20 times more potent than its uridine analogue 4, with no cytotoxicity observed for both compounds in GS4.1 cells for doses ≤75 μM (Table 3) . Once again, the corresponding SATE prodrugs 19 and 20 led to an increase of the antiviral activity (40-fold for the uracil derivative, Table 3 ) along with a higher cytotoxicity.
Inhibition of BVDV NS5B polymerase activity
To explore the mode of action of the studied 2′-C-methylribonucleoside analogues, triphosphates corresponding to all the D-enantiomers synthesized for this study, and one triphosphate derivative from the L-series, as a representative example, were prepared and assayed for inhibition of BVDV polymerase.
BVDV NS5B is a RDRP that catalyses the incorporation of nucleotides into the RNA product. To test the activity of BVDV NS5B polymerase, we used the synthetic RNA template (-21) derived from the 3′-terminal 21 nucleotides of BVDV's minus strand RNA (Kim et al., 2000) . We monitored the rate of RNA product formation by measuring incorporation of radioactively labelled nucleotide into the RNA synthesized on (-21) template in the absence or presence of modified 2′-C-methyl nucleoside triphosphates (2′-C-methyl NTPs). The ability of NS5B to synthesize RNA was inhibited by the D-2′-C-methylnucleoside triphosphates 29 and 30 derived from the two active ribonucleoside analogues 4 and 5, with IC 50 in the low micromolar range (Table 6) . Surprisingly, triphosphate 28 derived from the inactive 2′-C-methyl-thymidine (3) proved to be a weak inhibitor of the BVDV polymerase. In contrast to its D-enantiomer 29, which exhibited an IC 50 value of 1.90 μM (Table 6 ), L-2′-C-methyl-UTP (32) was found inactive when assayed against BVDV polymerase and did not reach 50% inhibition of BVDV polymerase activity at concentration ≤100 μM.
Thus, only the D-series of 2′-C-methylribonucleosides derived from the pyrimidine bases constitutive of natural RNA, which represents the most potent class of compounds identified so far as direct inhibitors of RNA virus replication, were considered for further metabolism, stability and safety studies.
Stability studies of 4 and 5 in acidic and neutral media
The selected compounds were incubated at 37˚C in buffer (pH 1.2), and in Milli-Q water (pH 6.3), and their eventual chemical hydrolysis was monitored by HPLC. 2′-C-Methyl-uridine (4) and 2′-C-methyl-cytidine (5) appeared to be fully stable at pH 1.2 and pH 6.3, respectively.
Intracellular metabolism of 4 and 5
The intracellular metabolism of 2′-C-methyl-uridine (4) and 2′-C-methyl-cytidine (5) prior to extraction and HPLC analysis. Cytidine derivative 5 was efficiently converted to its corresponding triphosphate 30 (5 triphosphate, Table 7 ). Interestingly, the formation of a second triphosphate (29, which is 4 triphosphate), corresponding to the deaminated metabolite of 5 (that is, 4), was observed in both cell types. No other metabolites were detected. On the other hand, deamination of the nucleoside 5 was not detected in human liver subcellular fractions or in the exposure media of HepG2 and MDBK cells, at any time point following exposure to 5. Moreover, only minor deamination (3% after 24 h of incubation) was observed in hepatocytes. 2′-C-Methyl-uridine (4) was also well phosphorylated in the cell systems used (Table 7) . No other metabolites were observed in either cell culture or human liver subcellular fractions. Owing to the lesser antiviral potency of 2′-Cmethyl-uridine (4), the sole cytidine derivative 5 was selected for safety evaluation studies.
Rat toxicity studies for 5
Potential acute toxicity of 2′-C-methyl-cytidine (5) was evaluated in one group of four female rats administered with the test compound by oral gavage, and was assessed by clinical observations and body weight measurements of the animals.
In single dose-escalation experiments in rats with compound 5, animals exhibited no adverse symptomatic signs following oral doses of 20 mg/kg (day 1), 50 mg/kg (day 4) and six consecutive daily doses of 100 mg/kg (day 7-12).
Discussion
RNA virus infections are a major health issue, causing millions of deaths annually throughout the world. The lack of truly efficient therapeutic agents for the treatment of several RNA-virus-associated diseases, including hepatitis C, meningitis and influenza, is a growing concern, and the discovery of more potent drugs is of utmost importance. In this regard, the success of antiviral therapies based on chemotherapeutic agents targeting the viral polymerases of HIV, HBV, herpes simplex virus and others, prompted us to consider the RDRP as a target. Actually, during the past few years, branched nucleosides have attracted much interest towards that purpose, and we were the first to identify and report the anti-RNA virus activity of 2′-C-methyl branched-sugar ribonucleoside derivatives (Sommadossi & La Colla, 2001a; Sommadossi & La Colla 2001b) . Several subsequent publications (Carroll et al. 2002; Carroll et al., 2003; Hong et al., 2003; Migliaccio et al., 2003; Roberts et al., 2003; An et al., 2004; Eldrup et al., 2004a; Eldrup et al., 2004b; Olsen et al., 2004; Ding et al., 2005) from other groups confirmed our initial findings, mainly for 2′-Cmethyl branched derivatives in the purine series. More recently, other types of branched nucleoside analogues have been reported as potent inhibitors of HCV polymerase (Klumpp et al., 2006; Murakami et al., 2007) .
In this report, we wanted to disclose our findings regarding the 2′-C-methylribonucleosides in the pyrimidine series as a potent class of inhibitors of RNA virus replication. Compounds in this study are characterized by the presence of a β-methyl substituent at the 2′-position of the sugar moiety, whereas the pyrimidine aglycone (uracil, cytosine, and thymine) was kept natural. We also considered D-nucleosides as well as their corresponding L-enantiomers, because, during recent decades, a number of nucleoside analogues possessing the unnatural β-Lconfiguration have emerged as potent or potential antiviral agents (Zemlicka 2000; Gumina et al., 2002; Mathé & Gosselin 2006) . Moreover, L-nucleosides may be endowed with lower host toxicity than their D-enantiomers and maintain good antiviral activity (Cui et al., 1996; Focher et al., 2003) .
Title compounds were evaluated against a large panel of RNA viruses, taking into account all three viral classes (ssRNA + , ssRNA -, and dsRNA), by using viruses representative of the Flaviviridae (BVDV, YFV, DENV-2, WNV, and HCV), Coronaviridae (HCoV), Retroviridae (HIV-1), Picornaviridae (CVB-2, and Polio-1), Paramyxoviridae (RSV), Rhabdoviridae (VSV) and Reoviridae (Reo-1). Although 2'-C-methyl-thymidine (3) was found inactive against all those viruses, 2′-C-methyl-uridine (4) and -cytidine (5) were shown to inhibit the replication of all the ssRNA + viruses in this study except HIV-1, which is not surprising since HIV reverse transcriptase uses deoxyribonucleotides and not ribonucleotides as substrates. Notably, cytidine derivative 5 was four to eightfold more potent than 4 against several viruses, with activity against BVDV in the low micromolar range without any toxicity for the host cell lines up to 100 μM. Superiority of 5 over 4 was even higher (20-fold) in HCV replicon. On the other hand, activity was only moderate against the dsRNA reovirus, and not detected against the ssRNAviruses, indicating a ssRNA + specificity for this class of compound. Cytotoxicity of the pyrimidine-branched nucleosides was also profiled using a large panel of cell lines, either in 
ND bis(S-pivaloyl-2-thioethyl)-phosphate (26) *Pestivirus. † Retroviridae. ‡ Coronavirus. § Compound concentration (μM) required to reduce the viability of mock-infected Madin-Darby bovine kidney (MDBK) cells by 50%, as determined by the 3 (4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) method. ¶ Compound concentration (μM) required to achieve 50% protection of preinfected MDBK cell lines from virus-induced cytopathogenicity, as determined by the MTT method. # Compound concentration (μM) required to achieve 50% protection of pretreated MDBK cell lines from virus-induced cytopathogenicity, as determined by staining with crystal violet. **Compound concentration (μM) required to reduce MT-4 (CD4 + human T-cells containing an integrated HTLV-1 genome) cell proliferation by 50%, as determined by the MTT method, under conditions that allow untreated controls to undergo at least three consecutive rounds of multiplication. † † Compound concentration (μM) required to achieve 50% protection of MT-4 cell lines from virus-induced cytopathogenicity, as determined by the MTT method. ‡ ‡ Compound concentration (μM) required to reduce the SK-MES-1 (human lung squamous carcinoma) cell number as determined by methylene blue staining. § § Compound concentration (μM) required to reduce the virus plaque number by 50% in SK-MES-1 cell lines. Data represent mean values for three independent determinations. Variation among duplicate samples was <15%. BVDV, bovine virus diarrhoea virus; HCoV, human corona virus; ND, not determined; ssRNA + , single-stranded positive RNA. (26) *Flavivirus. † Reovirus. ‡ Compound concentration (μM) required to reduce the viability of mock-infected baby hamster kidney cells (BHK) cells by 50%, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide method. § Compound concentration (μM) required to reduce the virus plaque number by 50% in BHK cell lines. Data represent mean values for three independent determinations. Variation among duplicate samples was <15%. DENV-2, dengue virus type 2; dsRNA, double-stranded RNA; Reo-1, reovirus type 1; ssRNA + , singlestranded positive RNA. WNV, West Nile virus; YFV, yellow fever virus. .3% ‡ bis(S-pivaloyl-2-thioethyl)-phosphate (26) *Single-stranded RNA genome. † Compound concentration (μM) required to reduce the viability of GS4.1 cells by 50%, as determined with the the Cell Titer 96 AQ ueous One Solution Cell Proliferation Assay (Promega Corp, Madison, WI, USA). ‡ Compound concentration (μM) required to reduce hepatitis C virus (HCV) replication by 50% as determined by the HCV replicon ELISA method. ‡ Percent inhibition of HCV replicon replication at the test concentration of 15 μM as determined by the HCV replicon ELISA. ND, not determined. Table 3 . Activity of 2'-C-methyl pyrimidine ribonucleosides in the HCV replicon system confluent monolayers or in exponentially growing cultures. D-nucleosides 3 and 4 did not show any cytotoxicity in the tested cell lines, and the cytidine derivative 5 was only moderately toxic for MT-4, CCRF-CEM, WIL-2NS, CCRF-SB and HepG2 cells.
Concerning the L-enantiomers, none of the 2′-Cmethyl branched L-ribonucleosides (12-14) showed any activity against the different classes of RNA viruses. To verify if this could be attributed to a problem of intracellular phosphorylation, nucleotidic prodrugs derived from uracil and cytidine L-nucleosides, the active compounds in the D-series, were prepared as representative examples of the L-series. The introduction in the 5′ position of compounds 13 and 14 of a bis(tBuSATE)phosphotriester moiety respectively led to the prodrugs 25 and 26, which were designed to be lipophilic enough to cross membranes, and deliver intracellularly the corresponding monophosphate after esterase hydrolysis (Lefebvre et al., 1995) . This concept of nucleotidic prodrug incorporating the enzymolabile monophosphate masking groups tBuSATE has been validated on numerous models, including the use of cell lines lacking the enzymes necessary for the monophosphorylation of the parent compound (Lefebvre et al., 1995) , or the derivatization of an inactive nucleoside analogue whose triphosphate derivative is a potent inhibitor of a viral polymerase (Périgaud et al., 1993) . Unfortunately, compounds 25 and 26 showed no antiviral activity, just as their parent derivatives. Other explanations than the sole nonmonophosphorylation of the L-nucleoside analogues should then be envisaged to explain their inactivity. Antiviral activities have already been reported for SATE pronucleotides derived from nucleoside analogues of diverse structures, including L-enantiomers (Placidi et al., 2001) , HCV-targeted derivatives or phosphonates (Benzaria et al., 1996) , but no precedent existed in the ribonucleoside analogue series at the time of our study. For this reason, we decided to investigate the same kind of modification on the corresponding D-2′-Cmethylribonucleosides as a control. Unlike its L-counterpart 25, the uracil phosphotriester derivative 19 resulted in significantly (5-40-fold) more potency than its parent compound 4 against both ssRNA + and dsRNA viruses. A similar increase in potency was observed for the cytosine phosphotriester derivative 20, except against BVDV and the enteroviruses, for which same potency as 5 was maintained. Considering that both 19 and 20 are released inside the cells as monophosphates of 4 and 5, respectively, the above results suggest that 4 is poorly phosphorylated in MDBK, BHK, Vero and SK-MES-1 cells, whereas 5 is poorly phosphorylated in BHK and SK-MES-1 cells, but is efficiently activated to monophosphate in MDBK and Vero cells. It should, however, be noted that the prodrugs 
>100 bis(S-pivaloyl-2-thioethyl)-phosphate (26) *Enterovirus. † Paramyxoviridae. ‡ Rhabdoviridae. § Compound concentration (μM) required to reduce the Vero (monkey kidney) cell number as determined by methylene blue staining. ¶ Compound concentration (μM) required to reduce the virus plaque number by 50% in Vero cell lines. Data represent mean values for three independent determinations. Variation among duplicate samples was <15%. CVB-2, coxsackie virus, B 2 strain; ND, not determined; Polio-1, poliovirus type-1; RSV, respiratory syncytial virus; ssRNA + , single-stranded positive RNA; ssRNA -, single-stranded negative RNA; VSV, vesicular stomatitis virus. Table 4 . Activity of 2'-C-methyl pyrimidine ribonucleosides against selected ssRNA + viruses (enteroviruses) and ssRNAvirus (RSV and VSV) in Vero cell lines also led to a greater cytotoxicity, which could be related to an increased intracellular accumulation of one of the phosphorylated metabolites. Moreover, the antiviral potency increase confirms that SATE pronucleotides are acting as prodrugs, leading to the intracellular delivery of the monophosphate derivatives, and ultimately to the accumulation of the corresponding triphosphates. This also suggests that the pyrimidine 2′-C-methylribonucleosides have a classical nucleoside analogue mode of action through metabolization to their triphosphates. To confirm such a mode of action, triphosphates were prepared and assayed for inhibition of BVDV polymerase. The D-2′-Cmethyl NTPs 29 and 30 derived from the two active ribonucleoside analogues 4 and 5, respectively, proved to be potent inhibitors of the enzyme. Thus, the anti-BVDV activity determined in cell culture experiments for compounds 4 and 5 should be attributable to a direct viral effect. Although we did not assay all individual polymerases of the different members of the Flaviviridae and Picornaviridae sensitive to the action of the 2′-C-methylribonucleosides, we could envisage a similar mode of action against those viruses. Indeed, sequence analyses demonstrate that certain key domains of RNA-dependent RNA polymerases are highly conserved among positive strand RNA viruses (Koonin & Dolja, 1993) . More importantly, and in agreement with the fact that BVDV could be considered as a surrogate model of HCV for the evaluation of antiviral agents (Buckwold et al., 2003; Standring et al., 2003) , the triphosphorylated derivative of 2'-C-methyladenosine and 2′-C-methyl-guanosine were also shown by other groups to inhibit purified HCV polymerase Migliaccio et al., 2003; Eldrup et al., 2004a) . We have also demonstrated in other studies that the mode (26) *CD4 + human acute T-lymphoblastic leukaemia; † Human splenic B-lymphoblastoid cells; ‡ Human acute B-lymphoblastic leukaemia; § Human skin melanoma; ¶ Human breast adenocarcinoma; # Human hepatocellular carcinoma; **Human prostate carcinoma; † † Human foreskin fibroblasts; ‡ ‡ Human lung fibroblasts. § § Compound concentration (μM) required to reduce cell proliferation by 50%, as determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide method, under conditions allowing untreated controls to undergo at least three consecutive rounds of multiplication. Data represent mean values for three independent determinations. Variation among duplicate samples was <15%. (Standring et al., 2003) , relative to the corresponding natural ribonucleoside triphosphate and involved chain termination. Surprisingly, triphosphate 28 derived from the inactive 2′-C-methylthymidine (3) proved to be a weak inhibitor of the BVDV polymerase, suggesting that the parent nucleoside 3 was not triphosphorylated in any of the cells used in our antiviral assays. Another hypothesis could be that triphosphate of 3 is be formed, but is competed out by UTP. Actually, mRNA and rRNA do not generally incorporate ribonucleotides derived from thymine, and when the latter thymine is present in the structure of tRNA, it is the result of a post-transcription methylation of an uracil derivative, not direct incorporation (Blackburn & Gait, 1996) . Alternatively, L-2′-C-methyl-UTP (32) was found inactive, suggesting that the 2′-C-methyl-branched L-ribofuranonucleosides, at least in the pyrimidine series, should not be considered for further development as anti-RNA virus agents.
We then focused only on the D active compounds 4 and 5 for further studies. The studies were designed to select the best candidate for development on the basis of sufficient chemical and enzymatic stability, efficient metabolism and safety. Both compounds appeared to be fully stable at pH 1.2 and pH 6.3, and thus should be sufficiently chemically stable in the gastrointestinal tract and biological fluids before their absorption, so could be suitable for an oral administration.
The intracellular metabolism of 2′-C-methyl-uridine (4) and 2′-C-methyl-cytidine (5) was studied in HepG2 and MDBK cells. Cytidine derivative 5 was efficiently converted to its corresponding triphosphate 30. We also noted the formation of the corresponding deaminated (uracil derivative) triphosphate (29) in both cell types. Deamination of cytidine derivative probably occurred at the monophosphate level, since no deamination was detected for the nucleoside 5 when exposed to human liver subcellular fractions, or culture media of HepG2 and MDBK cells. Moreover, we observed only minor deamination (3% after 24 h of incubation) in hepatocytes, and no deamination of 5 by partially purified human cytidine deaminase (data not shown). This is in agreement with the fact that nucleosides having 2′-ribose substitutions on the β face of the nucleoside, which are positioned cis relative to the 4′-hydroxymethyl of the ribose, are poor cytidine deaminase substrates (Krajewska & Shugar 1975; Kries et al., 1978) . Consistent with this, the lowest energy conformation predicted for the sugar of 2′-C-methyl-cytidine (5) is preferentially of the northern type, and its 2′-methyl group is cis relative to the 4′-hydroxymethyl of the ribose . 2′-C-Methyl-uridine (4) was also well intracellularly triphosphorylated, and no other metabolites were observed in either cell culture or human liver subcellular fractions. Owing to the lesser antiviral potency of 2′-C-methyl-uridine (4), we selected 2′-C-methyl-cytidine (5) as a potential development candidate for safety evaluation studies. Potential acute toxicity of 5 was evaluated in rats through oral gavage. The animals exhibited no adverse symptomatic signs following oral doses as high as 100 mg/kg. Therefore, 2′-C-methylcytidine (5) emerged as a safe compound, suitable for further development.
Conclusion
As part of an ongoing effort to develop new therapeutic agents against several life-threatening RNA virus infections, we report here a detailed study concerning ribonucleoside analogues retaining the three naturally occurring pyrimidine bases, and possessing a β-methyl substituent at the 2′-position of a D-or L-ribose moiety. In-vitro screening against a panel of RNA viruses revealed 2'-Cmethyl-cytidine (5) as a potent inhibitor of HCV and of the pestivirus BVDV, with some activity against Flaviviridae and Picornaviridae members. The mode of action of this analogue was shown to be targeting viral polymerases, through inhibition by the corresponding triphosphate derivative. Finally, comparative studies of intracellular metabolism, chemical and enzymatic stability, and safety in rats permitted the selection of 2′-C-methyl- *Compounds were incubated in cell culture for the times indicated, prior to extraction and analysis with HPLC. Data are expressed as pmol/million cells of corresponding triphosphates and are averages of at least four independent experiments; † Measurements of levels of 2'-C-methyl-uridine triphosphate formed following 5 exposure. MDBK, Madin-Darby bovine kidney; ND, not detected; TP, triphosphate. Table 7 . Intracellular 5'-triphosphate levels following incubation of 2'-C-methyluridine (4), and -cytidine (5) in cell culture (HepG2 and MDBK cells)* cytidine (5) as a valid candidate for development as an anti-RNA virus agent. Efforts have already been made for the determination of its pharmacokinetic parameters in animals, and the design of a suitable prodrug to enhance its oral bioavailability (Pierra et al. 2006 ), which will permit its clinical evaluation. A prodrug of 5 is currently undergoing Phase IIb clinical trials for the treatment of chronic HCV infection Zhou et al. 2005) .
